ASKLEP Inc.

Action for ACTS (Asian Clinical Trials and Solutions)

Due to the recent increase in globalization and borderlessness of new drug development in the pharmaceutical industry, “Simultaneous worldwide development of new drugs” and “Multinational clinical trials” have become commonplace. On the other hand, as so-called “Local Studies” only have long been conducted in Japan, we lag far behind other Asian nations in the conduct of “Global Studies”. In fact, “Drug Lag” has become a serious social problem in our nation. Reasons for drug lag include a lack of infrastructure maintenance and human resources for “Multinational clinical trials”.

With the increase in researches about genetic and racial characteristics of Asians including Japanese people, an idea that clinical trials in Asian regions are necessary and important emerges. As a result, the axis of “Multinational clinical trials” is shifting from “Global Studies” to “Regional Studies” in certain types of drugs and diseases for which internal and external factors of regions and ethnic groups cannot be ignored.

As the internationalization of drug development progresses, the hollowing-out of clinical trials conducted in Japan is becoming an issue. We believe that conducting “Regional Studies” will be a good opportunity for us to take the initiative in Asia in terms of new drug development.

ACTION for ACTS!

Under these circumstances, we, Asklep, set an “Action for ACTS (Asian Clinical Trials and Solutions)” as our corporate vision and have just begun to carry out our global strategy. We will aim to become a top ”Drug Lifecycle Solution Provider” in Asia and provide unique and high-quality solutions for clinical drug development and the subsequent life cycle management, targeting at clinical trials in Asian regions including Japan.